Medicalgorithmics S.A. — AGM Information 2022

Oct 28, 2022

MEDICALGORITHMICS S.A. EXTRAORDINARY GENERAL MEETING OF OCTOBER 28, 2022

DRAFT RESOLUTIONS

Resolution [∙]/10/2022 October 28, 2022 Extraordinary General Meeting of Medicalgorithmics S.A. based in Warsaw

Determination of the number of members in the Supervisory Board

Article 1

Pursuant to Article 385(1) of the Commercial Companies Code and in connection with Article 17.3 of the Company's Articles of Association, the General Meeting hereby decides that the Supervisory Board will have 6 (six) members.

Article 2

This resolution becomes effective on the day of its adoption.

Explanation: Upon the adoption of Resolution 7/10/2022 determining the number of members in the Supervisory Board, this draft resolution has become irrelevant and, therefore, was not voted.

Resolution [∙]/10/2022 October 28, 2022 Extraordinary General Meeting of Medicalgorithmics S.A. based in Warsaw

Election of the Chairperson of the Supervisory Board

Acting based on Article 385(1) of the Commercial Companies Code, in conjunction with Article 17.2 of the Articles of Association, the Extraordinary General Meeting hereby resolves as follows:

Article 1

• 1. The Extraordinary General Meeting resolves to choose Mr/Ms [∙] from among the members of the Supervisory Board to take the seat of the Chairperson of the Supervisory Board of the Company, from the time of adoption of this resolution to the date on which the commercial register of the National Court Register will disclose the increase of the Company's share capital as resolved by the General Meeting on the date of this resolution.
• 1. This Article 1 becomes effective once this resolution is adopted.

Article 2

• 1. The Extraordinary General Meeting resolves to choose Mr Paweł Lewicki to take the seat of the Chairperson of the Supervisory Board of the Company, on and after the date on which the commercial register of the National Court Register will disclose the increase of the Company's share capital as resolved by the General Meeting on the date of this resolution.
• 1. This Article 2 becomes effective once the last of the following conditions precedent becomes fulfilled:
  2. 1) the Company's bank account is credited with PLN 13,807,810.28 (thirteen million eight hundred and seven thousand eight hundred and ten zlotys and 28/100) from Biofund Capital Management LLC as payment towards the increase of the Company's share capital;
  3. 2) an agreement is executed that transfers onto the Company all (100%) shares in Kardiolytics Inc, based in Oklahoma, address: 296 Woodward Blvd. Tulsa, Oklahoma, 74114, a company registered in the

company registry under number 7063366, as payment towards the increase of the Company's share capital.

Explanation: Since no candidacy for the function of Chairperson of the Supervisory Board within the period indicated in Article 1(1) of this draft resolution was submitted, this draft resolution was not voted.